Agen Genomics files Form D for offering of up to $1.5 million
The California biotechnology company reported $25,000 sold toward the offering as of September 1, 2026, while its filing lists zero investors as having invested.
Agen Genomics, Inc., a biotechnology company based in Escondido, California, filed a Form D with the SEC disclosing a new securities offering. The company was incorporated in California within the last five years, in 2025.1
The filing lists a date of first sale of 2026-08-28.1 The securities offered are equity.1 The total offering amount is listed as $1,500,000, with $25,000 reported as the total amount sold and $1,475,000 remaining to be sold.1
The minimum investment accepted from any outside investor is set at $25,000.1 Despite the $25,000 in sales already recorded, the filing states the total number of investors who have already invested in the offering is 0.1
The offering claims exemption under Rule 506(b).1 The issuer indicated it intends the offering to last more than one year.1 The offering is not being made in connection with a business combination transaction such as a merger or acquisition.1
The filing reports no sales commissions or finders' fees paid in connection with the offering.1 Proceeds directed toward executive officers, directors, or promoters are listed at $25,000, marked as an estimate.1
Christopher Scott Lippe is named as a related person in the filing, identified as an executive officer.1 Lippe signed the Form D as CEO of Agen Genomics on 2026-09-01.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.